Aimei Health Technology Co, LTD

Aimei Health Technology Co., Ltd. announced the termination of its business combination agreement with United Hydrogen Group Inc., citing the occurrence of the applicable outside date.

Aimei Health Technology Co., Ltd. has extended its business combination deadline by one month to August 6, 2026, with an associated extension payment and a new promissory note.

Aimei Health Technology Co., Ltd announced the resignation of director Julianne Huh and the appointment of Daniel Veikko Polvi to its board.

Aimei Health Technology Co., Ltd. has extended its business combination deadline to July 6, 2026, by depositing $34,330.96 and issuing a promissory note.

Aimei Health Technology Co., Ltd. has extended its business combination deadline by one month to June 6, 2026, through a $34,330.96 extension payment funded by a promissory note.

Aimei Health Technology Co., Ltd. has received a notice from Nasdaq for failing to file its annual report on time, risking delisting if compliance is not regained.

Aimei Health Technology Co., Ltd. reports significant redemptions and a going concern warning as it pushes to finalize its business combination with United Hydrogen Group Inc. by early 2026.

Aimei Health Technology Co., Ltd. reports significant trust account redemptions and increased deficit, raising substantial doubt about its ability to continue as a going concern.

Aimei Health Technology Co., Ltd. reports its financial results for the quarter ended March 31, 2025, amidst ongoing efforts to complete a business combination.

Aimei Health Technology Co., Ltd. reported a net income of $743,510 for the third quarter of 2024, primarily driven by interest earned on investments held in trust, while also progressing towards a planned business combination with United Hydrogen Group.

Aimei Health Technology Co., Ltd. reported a net income of $1.36 million for the first six months of 2024 and announced a definitive merger agreement with United Hydrogen Group Inc.

Aimei Health Technology Co., Ltd., a blank check company, reported a net income of $755,500 for the quarter ended March 31, 2024, primarily driven by interest earned on investments held in trust.

Aimei Health Technology Co., Ltd. filed an amended annual report, providing extensive risk disclosures related to its proposed business combination with PRC-operating United Hydrogen Group Inc. and detailing financial results for 2024.

Aimei Health Technology Co., Ltd filed its annual report on Form 10-K, highlighting its ongoing efforts to complete a business combination with United Hydrogen Group Inc.

Aimei Health Technology Co., Ltd.'s 10-K filing outlines the company's share structure, voting rights, and plans for a business combination, while also detailing potential risks and conflicts of interest.

Mizuho Securities USA LLC, a 10% owner of Aimei Health Technology Co., Ltd., disposed of 150,000 shares of common stock on February 11, 2025.

Aimei Health Technology Co., Ltd. is seeking shareholder approval to extend its business combination deadline to December 2026 and reduce sponsor extension fees to facilitate its merger with United Hydrogen.

Aimei Health Technology Co., Ltd. (Aimei Health) has announced a definitive business combination agreement to merge with United Hydrogen Group Inc., forming United Hydrogen Global Inc. (Pubco), a hydrogen solutions provider, in a $1.5 billion all-stock transaction.

Aimei Health Technology Co., Ltd. announced the adjournment of its Extraordinary General Meeting to February 5, 2025.

Aimei Health Technology is seeking shareholder approval to amend its Investment Management Trust Agreement, increasing the monthly extension fee from $0.033 per public share to $150,000 for all outstanding public shares, to extend the period for completing its initial business combination.

Aimei Health Technology Co., Ltd is holding an extraordinary general meeting to vote on amendments to its articles of association and trust agreement, as well as to ratify the appointment of its auditor.

Aimei Health Technology Co., Ltd is seeking shareholder approval to amend its Investment Management Trust Agreement to reduce the required monthly extension fees, aiming to facilitate a business combination.

Mizuho Financial Group reports 0% beneficial ownership in Aimei Health Technology Co., Ltd. common shares in its latest Schedule 13G amendment.

Karpus Management, Inc. reported a 1.28% beneficial ownership stake in Aimei Health Technology Co., Ltd. as of December 31, 2025.

Wolverine Asset Management and its affiliates have filed an amended Schedule 13G, reporting zero beneficial ownership in Aimei Health Technology Co., Ltd.

Mizuho Financial Group, Inc. has disclosed a 9.0% beneficial ownership stake in Aimei Health Technology Co., Ltd. through its subsidiaries.

W. R. Berkley Corporation and its subsidiary Berkley Insurance Company have disclosed a 6.9% beneficial ownership stake in Aimei Health Technology Co., Ltd, totaling 425,361 ordinary shares.

Mizuho Financial Group, Inc. has filed an amended Schedule 13G, revealing a 9% beneficial ownership stake in Aimei Health Technology Co., Ltd. as of March 31, 2025.